Physician profile
Amjad Ali
NPI 1699935650
$10,209.87
in general payments reported to CMS, 2019-2025
28 companies · $1,732 in 2025
The $1,732 reported for 2025 was more than what 84% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $176 · 2020: $89.41 · 2021: $1,106 · 2022: $2,702 · 2023: $2,113 · 2024: $2,292 · 2025: $1,732.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,051 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $53.00 · Gift: $20.00 · Education: $12.73.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,051.17 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $53.00 |
| Gift | $20.00 |
| Education | $12.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $2,851.14 | 2020-2024 | Xarelto |
| Melinta Therapeutics, LLC | $1,683.59 | 2021-2025 | Kimyrsa, Rezzayo, Orbactiv |
| Shionogi INC | $1,116.10 | 2021-2025 | Fetroja |
| Abbvie INC. | $1,115.54 | 2021-2025 | Teflaro, Avycaz, Dalvance |
| Merck Sharp & Dohme LLC | $804.83 | 2019-2025 | Zerbaxa, Dificid, Capvaxive |
| Gilead Sciences, INC. | $408.33 | 2021-2025 | Yeztugo |
| E.R. Squibb & Sons, L.L.C. | $387.64 | 2019-2024 | Opdivo, Camzyos |
| La Jolla Pharmaceutical Company | $370.11 | 2023-2025 | Xacduro, Xerava, Zevtera |
| Pfizer INC. | $327.07 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $159.65 | 2022-2025 | Dupixent |
| Amgen INC. | $125.00 | 2025 | Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $125.00 | 2024 | Lifevest |
| Genzyme Corporation | $115.03 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $89.36 | 2022-2025 | Jardiance |
| Cumberland Pharmaceuticals, INC. | $88.37 | 2022-2025 | Vibativ |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viatris Specialty LLC | $55.09 | 2025 | Yupelri |
| Allergan, INC. | $54.97 | 2019-2020 | |
| Becton, Dickinson and Company | $53.00 | 2024 | Site-Rite |
| Insmed, INC. | $48.09 | 2025 | Arikayce |
| Medtronic, INC. | $45.00 | 2022 | |
| Paratek Pharmaceuticals, INC. | $42.21 | 2025 | Nuzyra |
| Geron Corporation | $28.99 | 2025 | Rytelo |
| Mylan Specialty L.P. | $23.23 | 2022 | |
| Memed US, INC. | $20.00 | 2025 | Memed Bv |
| Takeda Pharmaceuticals U.S.A., INC. | $19.90 | 2024 | Fruzaqla |
| Ucb, INC. | $18.40 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $17.93 | 2023 | Andexxa |
| Smith+Nephew, INC. | $16.30 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amjad Ali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.